The DOI matches its Crossref record.
Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testicular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for Research and Treatment of Cancer Trial 30942 (ISRCTN18525328)
Open accessAbstract
European Organisation for Research and Treatment of Cancer Trial 30942 (ISRCTN18525328)TO THE EDITOR: I would like to congratulate the efforts of Jones et al 1 for their article published in the February 20 issue of the Journal of Clinical Oncology, in which they defined the appropriate radiation dose in the adjuvant treatment of stage I seminoma.It was a well done randomized trial, which tried to answer several important questions in the treatment of seminoma.Nearly 90% of the patients in the study received para-aortic strip only irradiation (PAS), without treatment to the pelvis.With reference to Table 3 of their article, I have several questions and comments.The recurrence pattern is very interesting to look at, even though it is for a small number, which has its limitations.Six (60%) of the 10 recurrences in the 30-Gy group were in the pelvic nodes, whereas three (27%) of 11 in the 20-Gy group were in the pelvic nodes.The locations of the pelvic nodes recurrences were not mentioned, so we could not see whether these recurrences could potentially have been prevented by the use of the dogleg (DL) field.If we accept the conclusions of the study, ie, 20 Gy is as effective as 30 Gy, and then we retrospectively look from the treatmentfield perspective, only 1/5 of the recurrences in the DLtreated patients was in the pelvic nodes, whereas for eight of 16 patients in the PAS-treated group the recurrences were in the pelvis.The difference in the abdominal recurrences in both groups is not as dramatic (DL, one of five; PAS, three of 16).That is as far as what can be dissected out from these data on such a small number of events.However, the data suggest (1) 20 Gy versus 30 Gy is about the same in preventing para-aortic recurrences; (2) the addition of pelvic radiation may reduce pelvic node recurrences (if these recurrences were in the potential DL fields).If that is the case, the patients in the 30-Gy group may actually have a lower overall recurrence rate (four nonpelvic-node recurrences) compared with the 20-Gy group (eight nonpelvic node recurrences), which in turn may change the overall results in the trial.This certainly opens up another can of worms in term of considering the need of using the DL field again for the treatment of stage I seminoma for doses like 20 Gy.I hope the authors can address my concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
Travis, L. B., Fosså, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., Hall, P., Holowaty, E., Andersen, A., Pukkala, E., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji278 · Cited by 823
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
Interventions to enhance return-to-work for cancer patients
de Boer, A. G., Taskila, T. K., Tamminga, S. J., Feuerstein, M., Frings-Dresen, M. H., & Verbeek, J. H. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007569.pub3 · Cited by 428
Horwich, A., Shipley, J., & Huddart, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68305-0 · Cited by 398
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy217 · Cited by 326
Metadata
- Authors
- Chan, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-20
- Volume
- 23
- Issue
- 27
- Pages
- 6806-6806
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4249100950
- Cited by
- 230
- References
- 0
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testicular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). https://app.cochat.ai/papers/10.1200/jco.2005.01.8978
- The paper
- Chan, R. (2005). Randomized Trial of 30 Versus 20 Gy in the Adjuvant Treatment of Stage I Testicular Seminoma: A Report on Medical Research Council Trial TE18, European Organisation for Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.01.8978
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.